Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer

NCT00598091 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT00598091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00598091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer
Lead sponsor
Duke University
Phase
Phase 1
Overall status
Terminated
Start date
April 30, 2007
Completion date
May 31, 2012
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma, refractory solid tumors